TCGA-E2-A1IH-01A-11R-A13Q-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 34
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- INFLAMMATORY_RESPONSE+0.490
- TNFA_SIGNALING_VIA_NFKB+0.490
- KRAS_SIGNALING_UP+0.480
- ANGIOGENESIS+0.440
- COMPLEMENT+0.420
- IL6_JAK_STAT3_SIGNALING+0.420
- PANCREAS_BETA_CELLS+0.390
- UV_RESPONSE_DN+0.360
Top 10 suppressed
- MYC_TARGETS_V2-0.370
- MITOTIC_SPINDLE-0.350
- G2M_CHECKPOINT-0.330
- DNA_REPAIR-0.300
- E2F_TARGETS-0.290
- GLYCOLYSIS-0.280
- PEROXISOME-0.190
- MTORC1_SIGNALING-0.170
- FATTY_ACID_METABOLISM-0.160
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR35579817 | — | A | 0.909 |
| 2 | SRR23303737 | — | — | 0.898 |
| 3 | X038167c2.c7d9.47a2.9172.1cfe391c8131 | — | cohortMD2 | 0.884 |
| 4 | SRR8518350 | — | A | 0.883 |
| 5 | TCGA-XF-AAME-01A-12R-A42T-07 | — | — | 0.881 |
| 6 | SRR33346958 | — | — | 0.880 |
| 7 | MDT-AP-2658 | Med | Medulloblastoma | 0.875 |
| 8 | TCGA-AN-A0FN-01A-11R-A034-07 | — | A | 0.875 |
| 9 | MDT-AP-2743 | Med | Medulloblastoma | 0.868 |
| 10 | SRR15069613 | — | — | 0.865 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.490 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.480 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.390 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.140 | Inavolisib | — uncovered |
| HYPOXIA | 0.080 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.080 | Remibrutinib | — uncovered |